BCL-2 inhibitor yields high response in CLL and SLL.
Preliminary results from an ongoing phase I clinical trial of the B-cell lymphoma-2 oral inhibitor ABT-199 demonstrated an overall response rate of 84% among 67 patients with relapsed or treatment-resistant chronic lymphocytic lymphoma or small lymphocytic lymphoma.